Cancer-associated fibroblast

Cancer-associated fibroblast Cancer-associated fibroblasts are stromal cells that reside within solid tumor microenvironments and modulate cancer behavior through extracellular matrix remodeling, paracrine signaling, and metabolic crosstalk. Originating from diverse sources including resident fibroblasts, mesenchymal stem cells, and perivascular cells, they are implicated across many malignancies in driving invasion, immune evasion, and therapeutic resistance. Descriptions of their biology intersect with studies by clinicians and institutions investigating tumor heterogeneity, and their targeting is an active focus of oncology consortia and pharmaceutical development.

Definition and origin

Cancer-associated fibroblasts are defined as activated, non-neoplastic stromal fibroblastic cells present in the tumor stroma and are distinguished functionally from quiescent fibroblasts studied in classical pathology and by surgical teams at centers like Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Johns Hopkins Hospital. Their origins have been traced using lineage-tracing approaches developed by laboratories associated with institutions such as Massachusetts Institute of Technology and Harvard University, implicating sources including local tissue fibroblasts, bone marrow-derived mesenchymal stem cells linked to Dana-Farber Cancer Institute research, epithelial-to-mesenchymal transition noted in studies from University of California, San Francisco, endothelial-to-mesenchymal transition reported by groups at Stanford University School of Medicine, and pericyte conversion observed in investigations at University of Oxford. Clinical observations from centers like Cleveland Clinic and translational programs at National Institutes of Health have helped map CAF emergence in carcinomas, sarcomas, and desmoplastic tumors treated at comprehensive cancer centers such as MD Anderson Cancer Center.

Heterogeneity and markers

Heterogeneity among fibroblasts has been cataloged by consortia and laboratories at institutions including Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, and California Institute of Technology using single-cell sequencing platforms originally advanced by teams at Broad Institute of MIT and Harvard and Stanford University. Distinct CAF subsets are characterized by differential expression of markers investigated in studies from University College London and Karolinska Institutet; commonly reported proteins include alpha-smooth muscle actin noted in histopathology reports from Royal Marsden Hospital, fibroblast activation protein highlighted in translational studies at Imperial College London, platelet-derived growth factor receptors referenced in pharmacology work at Pfizer, and podoplanin evaluated in analyses from University of Tokyo. Additional markers such as fibroblast-specific protein 1 have been described in publications from Cold Spring Harbor Laboratory, while matrix metalloproteinases were characterized in biochemistry research at Max Planck Society. Large-scale atlases compiled by initiatives like the Human Cell Atlas and projects funded by the European Research Council have annotated spatial and temporal CAF diversity across malignancies treated at cancer centers including Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.

Roles in tumor progression

Cancer-associated fibroblasts contribute to tumor progression through mechanisms documented in preclinical and clinical studies from groups at Columbia University, Yale University, and University of Cambridge. They produce extracellular matrix components and remodeling enzymes described in research from Johns Hopkins University and secrete growth factors such as transforming growth factor-beta studied at National Cancer Institute and hepatocyte growth factor investigated in collaborations with Roche. CAFs promote invasion and metastasis as noted in clinical pathology cohorts from Mayo Clinic and can induce angiogenesis through VEGF signaling explored by teams at Novartis. They modulate therapeutic resistance to chemotherapy and targeted agents reported in trials run by cooperative groups like the European Organisation for Research and Treatment of Cancer and the National Comprehensive Cancer Network, and influence tumor dormancy and progression in longitudinal studies performed at Stanford University School of Medicine and University of California, Los Angeles.

Interactions with the tumor microenvironment

CAFs shape the tumor microenvironment by interacting with immune cells, endothelial cells, and cancer cells in contexts examined by immunology groups at Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, and Scripps Research. They secrete chemokines and cytokines such as CXCL12 and IL-6 characterized in translational immunology studies from Imperial College London and University of Michigan Medical School, recruiting regulatory immune populations described in reports from University of Pennsylvania and modulating checkpoint pathways targeted in trials conducted by Bristol Myers Squibb and Merck & Co.. CAF-mediated matrix stiffening and interstitial pressure alterations were quantified in biomechanics studies at ETH Zurich and Massachusetts Institute of Technology, affecting drug distribution evaluated in pharmacology research at GlaxoSmithKline and AstraZeneca. Crosstalk with perivascular niches and neural elements has been explored in neuroscience-oncology collaborations at University of Toronto and University of Sydney.

Therapeutic targeting and clinical implications

Therapeutic strategies targeting CAFs have been pursued by academic–industry consortia and clinical trial groups such as those at National Cancer Institute and pharmaceutical companies including Roche, Novartis, and Pfizer. Approaches include enzymatic degradation of stroma investigated in trials led by teams at MD Anderson Cancer Center, inhibition of fibroblast activation pathways pursued in programs at Eli Lilly and Company, and reprogramming of CAFs toward a quiescent phenotype explored in translational research at University College London. Immune-modulatory combinations integrating CAF-targeting agents with immune checkpoint blockade have been evaluated in studies organized by cooperative groups like the American Society of Clinical Oncology and regulatory assessments by agencies such as the Food and Drug Administration. Clinical implications extend to biomarker development for patient selection in precision oncology initiatives at Broad Institute of MIT and Harvard and health systems implementing molecular tumor boards at institutions like Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Ongoing multicenter trials and collaborative networks continue to define safety, efficacy, and the prognostic significance of CAF-directed interventions.

Category:Stromal cells